
Trial Protocol

A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with structural heart disease

BETA3_LVH

Coordinating investigator

Prof. Jean-Luc Balligand
Full professor, Head of Department
Pharmacology and Therapeutics (FATH)
Avenue Mounier, 52, B1.53.09
1200 Brussels, Belgium
Phone: +32-2-7645260/+32-2-7645262
Fax: +32-2-7645269

Biometry

Dr. Oana Brosteanu, Dr. Dirk Hasenclever
Clinical Trial Centre Leipzig
Universität Leipzig
Härtelstraße 16-18,
04107 Leipzig, Germany
Phone: +49-341-97 16 250
Fax: +49-341-97 16 189

Sponsor

UNIVERSITÉ CATHOLIQUE DE LOUVAIN
PLACE DE L UNIVERSITE 1, 1348 LOUVAIN LA NEUVE, Belgium

Date: November 3rd, 2016

Version: Final 5.0

EudraCT-Nr.: 2015-003146-75

Clinical Trials.gov identifier: NCT02599480

ISRCTN-Number: ISRCTN65055502

© Version 08 valid as of 01 January 2013

Print: [xxx]

Written by/authors:

Based on the protocol template from the Zentrum für
Klinische Studien Leipzig - KKS.

Table of Contents

	PAGE
GENERAL INFORMATION.....	6
Responsible Parties	6
Synopsis	10
Schedule of Assessments and Procedures	Erreur ! Signet non défini.
1 RATIONALE.....	ERREUR ! SIGNET NON DEFINI.
1.1 Medical Background	Erreur ! Signet non défini.
1.2 Rationale	Erreur ! Signet non défini.
1.3 Risk-Benefit Considerations.....	Erreur ! Signet non défini.
2 OBJECTIVES.....	ERREUR ! SIGNET NON DEFINI.
2.1 Primary Objective	Erreur ! Signet non défini.
2.2 Secondary Objectives	Erreur ! Signet non défini.
3 TRIAL DESIGN AND DESCRIPTION.....	ERREUR ! SIGNET NON DEFINI.
3.1 Trial Design	Erreur ! Signet non défini.
3.2 Requirements at the Trial Sites regarding Personnel and Equipment.....	Erreur ! Signet non défini.
3.3 Trial Sites and Number of Trial Subjects	Erreur ! Signet non défini.
3.4 Expected Duration of Trial	Erreur ! Signet non défini.
3.5 Premature Termination of the Trial	Erreur ! Signet non défini.
4 TRIAL SUBJECTS	ERREUR ! SIGNET NON DEFINI.
4.1 Inclusion Criteria	Erreur ! Signet non défini.
4.2 Exclusion Criteria.....	Erreur ! Signet non défini.
4.3 Justification for the Inclusion of vulnerable Populations ..	Erreur ! Signet non défini.
4.4 Participation in more than one Clinical Trial	Erreur ! Signet non défini.
4.5 Statement on the Inclusion of Dependent Individuals.....	Erreur ! Signet non défini.
4.6 Rationale for Gender Distribution.....	Erreur ! Signet non défini.
5 INVESTIGATIONAL PRODUCT.....	ERREUR ! SIGNET NON DEFINI.
5.1 Trial Drugs	Erreur ! Signet non défini.
5.2 Packaging and Labelling of the Trial Drug	Erreur ! Signet non défini.
5.3 Drug Accountability	Erreur ! Signet non défini.
5.4 Administration of the Study Drug	Erreur ! Signet non défini.
5.5 Blinding and Unblinding	Erreur ! Signet non défini.
6 INDIVIDUAL TRIAL PROCEDURES.....	ERREUR ! SIGNET NON DEFINI.
6.1 Patient Information and Informed Consent.....	Erreur ! Signet non défini.
6.2 Enrolment in the Trial.....	Erreur ! Signet non défini.
6.3 Description of the Treatment Procedures.....	Erreur ! Signet non défini.
6.4 Premature Termination of the Therapy for Individual Patients.....	Erreur ! Signet non défini.
6.5 Premature study termination for individual patients.....	Erreur ! Signet non défini.
6.6 Plan for Further Treatment.....	Erreur ! Signet non défini.
7 METHODS OF DIAGNOSTICS AND DATA SAMPLING.....	ERREUR ! SIGNET NON DEFINI.
8 ADVERSE EVENTS (AE/SAE).....	ERREUR ! SIGNET NON DEFINI.
8.1 Adverse Events (AE)	Erreur ! Signet non défini.

8.2	Safety Analysis	Erreur ! Signet non défini.
8.3	Concomitant Diseases	Erreur ! Signet non défini.
8.4	Serious Adverse Events (SAE)	Erreur ! Signet non défini.
8.5	Periodic Reports	Erreur ! Signet non défini.
8.6	Suspected Unexpected Serious Adverse Reactions (SUSAR)	Erreur ! Signet non défini.
8.7	Other Safety Relevant Issues	Erreur ! Signet non défini.
8.8	Therapeutic Procedures	Erreur ! Signet non défini.
8.9	Dealing with Pregnancy	Erreur ! Signet non défini.
9	BIOMETRY	ERREUR ! SIGNET NON DEFINI.
9.1	Biometrical Aspects of the Trial Design	Erreur ! Signet non défini.
9.2	End Points	Erreur ! Signet non défini.
9.3	Statistical Description of the trial hypothesis	Erreur ! Signet non défini.
9.4	Sample Size Discussion	Erreur ! Signet non défini.
9.5	Statistical Methods	Erreur ! Signet non défini.
9.6	Statistical Monitoring	Erreur ! Signet non défini.
9.7	Interim Analysis	Erreur ! Signet non défini.
9.8	Final Analysis	Erreur ! Signet non défini.
10	CONCOMITANT SCIENTIFIC PROJECTS	ERREUR ! SIGNET NON DEFINI.
10.1	Endothelial Function/Pulse amplitude tonometry and measurement of HbNO	Erreur ! Signet non défini.
10.2	Abundance/activity of brown/beige fat	Erreur ! Signet non défini.
10.3	Analysis of blood and urine samples for scientific purposes related to cardiac disease	Erreur ! Signet non défini.
11	ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS	ERREUR ! SIGNET NON DEFINI.
11.1	GCP-Statement	Erreur ! Signet non défini.
11.2	Initial Submission	Erreur ! Signet non défini.
11.3	Protocol Amendments	Erreur ! Signet non défini.
12	DOCUMENTATION	ERREUR ! SIGNET NON DEFINI.
12.1	Case Report Forms (CRF)	Erreur ! Signet non défini.
12.2	Data Management	Erreur ! Signet non défini.
12.3	Archiving	Erreur ! Signet non défini.
13	SUPERVISION OF THE CLINICAL TRIAL	ERREUR ! SIGNET NON DEFINI.
13.1	Access to Source Data	Erreur ! Signet non défini.
13.2	Monitoring	Erreur ! Signet non défini.
13.3	Audits	Erreur ! Signet non défini.
13.4	Inspections	Erreur ! Signet non défini.
13.5	Independent Supervision of the Trial	Erreur ! Signet non défini.
14	DATA PROTECTION AND CONFIDENTIALITY	ERREUR ! SIGNET NON DEFINI.
14.1	Declaration regarding Data Protection	Erreur ! Signet non défini.
14.2	Declaration regarding the Pseudonymized Transfer of Personal Data	Erreur ! Signet non défini.
15	ADMINISTRATIVE AGREEMENTS	ERREUR ! SIGNET NON DEFINI.
15.1	Adherence to the Protocol	Erreur ! Signet non défini.
15.2	Funding and Insurance	Erreur ! Signet non défini.
15.3	Notification of the Local Authorities (Germany only)	Erreur ! Signet non défini.
15.4	Publication Policy and Registration	Erreur ! Signet non défini.

16	REFERENCES	ERREUR ! SIGNET NON DEFINI.
17	PROTOCOL SIGNATURES	ERREUR ! SIGNET NON DEFINI.
18	PROTOCOL AGREEMENT	ERREUR ! SIGNET NON DEFINI.
19	APPENDIX	ERREUR ! SIGNET NON DEFINI.
19.1	Classification of Adverse Events	Erreur ! Signet non défini.
19.2	Definitions	Erreur ! Signet non défini.
19.3	Acronyms	Erreur ! Signet non défini.
19.4	Labelling	Erreur ! Signet non défini.

List of Tables

table 1: Schedule of Assessments and Procedures	Erreur ! Signet non défini.
---	------------------------------------

List of Figures

Figure 1: Flowchart of the trial	Erreur ! Signet non défini.
Figure 2: Sample of blister-label	Erreur ! Signet non défini.
Figure 3: Sample of box-label	Erreur ! Signet non défini.

GENERAL INFORMATION

Responsible Parties

Sponsor (according to Belgian drug law)	Université catholique de Louvain (UCL) Place de l'Université 1 1348 Louvain la Neuve Belgium Authorised representative of the sponsor, Promotor: Prof. Jean-Luc Balligand
Coordinating investigator(s)	Prof. Dr. Jean-Luc Balligand Full professor, Head of Department Pharmacology and Therapeutics (FATH) Avenue Mounier, 52, B1.53.09 1200 Brussels, Belgium Phone: +32-2-7645260/+32-2-7645262 Fax: +32-2-7645269 E-Mail: jean-luc.balligand@uclouvain.be
Deputy of Coordinating investigator	Anne-Catherine Pouleur Cliniques universitaires Saint-Luc Avenue Hippocrate, 10 1200 Bruxelles, Belgique Phone: +32-2-764 28 12, Fax: +32-2-764 89 80 E-Mail: anne-catherine.pouleur@uclouvain.be
Project Management	Dr Ir Nancy van Overstraeten UCL-FATH Institut de Recherche Expérimentale et Clinique (IREC) Building Vésale 5th floor ; 52 Avenue Mounier B1.53.09; 1200 Brussels; Belgium Phone: +32-2-764 52 88 Fax: +32-2-764 5269 E-Mail: nancy.vanoverstraeten@uclouvain.be Dr. Petra Neuhaus Zentrum für Klinische Studien Leipzig – KKS Universität Leipzig Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16255 Fax: +49 341 97 16 16189 E-Mail: petra.neuhaus@zks.uni-leipzig.de
Pharmacovigilance	Madlen Dörschmann Zentrum für Klinische Studien Leipzig – KKS Universität Leipzig

	<p>Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16129 Fax: +49 341 97 16 16278 E-Mail: madlen.doerschmann@zks.uni-leipzig.de</p>
Data Management	<p>Angelika Beyer Zentrum für Klinische Studien Leipzig – KKS Universität Leipzig Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16261 Fax: +49 341 97 16259 E-Mail: angelika.beyer@zks.uni-leipzig.de</p>
Biometry	<p>Dr. Oana Brosteanu Zentrum für Klinische Studien Leipzig – KKS Universität Leipzig Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16251 Fax: +49 341 97 16189 E-Mail: oana.brosteanu@zks.uni-leipzig.de</p> <p>Dr. Dirk Hasenclever Institut für Medizinische Informatik, Statistik und Epidemiologie Universität Leipzig Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16121 Fax: +49 341 97 16109 E-Mail: dirk.hasenclever@imise.uni-leipzig.de</p>
Monitoring	<p>Nicole Köppe-Bauernfeind Zentrum für Klinische Studien Leipzig – KKS Universität Leipzig Härtelstraße 16-18, 04107 Leipzig, Germany Phone: +49 341 97 16266 Fax: +49 341 97 16259 E-Mail: nicole.koepp-bauernfeind@zks.uni-leipzig.de</p>
Funding	<p>EU Framework Programme for Research and Innovation, Horizon 2020: Mr. Grzegorz OWSIANIK Marie-Christine Groenen Medical research and the challenge of ageing European Commission DIRECTORATE-GENERAL FOR RESEARCH & INNOVATION Medical research and the challenge of ageing Directorate Health</p>

	<p>B-1049 Brussels Belgium</p> <p>Phone: +32 22951192 E-Mail: Grzegorz.OWSIANIK@ec.europa.eu Marie-Christine.Groenen@ec.europa.eu</p>
Data Safety and Monitoring Board	<p><i>Organisation:</i> Prof. Dr. Stefan Anker Charité - Universitätsmedizin Berlin Campus Virchow-Klinikum Augustenburger Platz 1, 13353 Berlin, Germany Phone: +49 (0) 30-450 553463 Fax: +49 (0) 30-450 553951 E-Mail: s.anker@cachexia.de</p> <p><i>Chair:</i> Karl Swedberg, Prof. MD Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, and National Heart and Lung Institute, Imperial College, London, UK E-mail: karl.swedberg@gu.se</p> <p><i>Members:</i> Dan Atar, MD, FESC, FACC, FAHA Professor of Cardiology Head of Research, Div. of Medicine Oslo University Hospital, Ullevål Kirkeveien 166, Building 3-A N - 0407 Oslo - Norway Ph: + 47 22 11 91 00 Email W: dan.atar@ous-hf.no Email H: dan.atar@online.no</p> <p>Luigi Tavazzi, MD, FESC, FACC GVM Care and Research, E.S. Health Science Foundation, Maria Cecilia Hospital Via Corriera, 1 48010 Cotignola (RA) - Emilia-Romagna Italy E-mail: 'Elisa Ghizzardi GVM Care&Research' <direzionescientifica-mch@gvmnet.it></p> <p>Hans Wedel KB Biostatistics Apelsingatan 115</p>

	<p>426 54 Västra Frölunda Phone: 070-829 72 88 E-mail : hans.wedel@biostat.se</p>
Concomitant scientific projects	<p><u>Endothelial Function/Pulse amplitude tonometry and measurement of HbNO:</u> Dr Ignatios Ikonmidis, MD, PhD, FESC Assistant Professor, Member of EACVI Nucleus member of ESC WG Peripheral Circulation 2nd Cardiology Department University of Athens Attikon Hospital Rimini 1, 12462 Haidari, Greece E-mail: ignoik@otenet.gr, ignoik@gmail.com tel +30 6944805732 fax +30 210 5832351 , 210 5832192</p> <p><u>Abundance/activity of brown/beige fat:</u> Dr Renaud Lhommel (CUSL) Cliniques universitaires Saint-Luc Avenue Hippocrate, 55 bte B1.55.01 1200 Bruxelles Belgique Phone: +32 2 764 25 82 Fax: +32 2 764 16 02 E-Mail: renaud.lhommel@uclouvain.be</p>

Synopsis

Title of the trial	A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with structural heart disease.
Acronym	BETA3_LVH
Indication	Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).
Primary goal of the trial / primary end point	<p>The primary objective is to evaluate the effect of mirabegron (a new β3-specific agonist) on change in left ventricular mass and/or changes in diastolic function after 12 months of treatment in patients with cardiac structural remodeling with or without symptoms of heart failure (maximum NYHA II).</p> <p><u>Two equally ranked, primary endpoints:</u></p> <ul style="list-style-type: none"> • Change in left ventricular mass index (LVMI in g/m^2, defined as left ventricular mass divided by body surface) measured at baseline and 12 months after randomisation. • Change in diastolic function, assessed as the ratio of peak early transmitral ventricular filling velocity to early diastolic tissue Doppler velocity (E/e') measured at baseline and 12 months after randomisation.
Secondary goals of the trial / secondary end points	<p>Effect of mirabegron on other indicators for diastolic heart disease, i.e. cardiac fibrosis, left atrial volume index, diastolic function (E/e'), maximal exercise capacity and laboratory markers (analysed after 6 or 12 months of mirabegron treatment).</p> <p><u>Secondary endpoints:</u></p> <ul style="list-style-type: none"> • Further MRI endpoints (all measured in the central MRI core lab) <ul style="list-style-type: none"> - Cardiac fibrosis at baseline and at 12 months. Fibrosis is a key pathogenic mechanism of diastolic dysfunction, which is at the origin of HFpEF - Left atrial volume index at baseline and at 12 months. This parameter determines diastolic filling (and was shown to predict treatment efficacy in HFpEF in the J-DHF trial (Yamamoto et al. 2013)) - LV mass index (by cardiac MRI) at 6 months, - Diastolic function (E/e') at 6 months; • Laboratory parameters at baseline and at 3, 6 and 12 months <ul style="list-style-type: none"> - serum biomarkers (Galectin3, GDF15, NT-proBNP, hsTnT) - metabolic parameters (fasting glucose, modified HOMA test, HbA1c, serum lipids) • Maximal exercise capacity (peak VO_2) at baseline and 12 months.

	<ul style="list-style-type: none"> • Safety endpoints <ul style="list-style-type: none"> - Incidence, severity and frequency of adverse and serious adverse events - Mortality
Trial design	Two armed, prospective, randomized, placebo-controlled, multi-centric international phase IIb trial
Trial population	<p><u>Inclusion criteria:</u></p> <ul style="list-style-type: none"> • Age between 18 and 90 years • Morphological signs of structural cardiac remodelling by echocardiography, i.e. increased LV mass index ($\geq 95 \text{ g/m}^2$ or higher for female; $\geq 115 \text{ g/m}^2$ or higher for male subjects (Ponikowski et al. 2016)) or end-diastolic wall thickness $\geq 13 \text{ mm}$ in at least one wall segment • Written informed consent For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject. <p><u>Major exclusion criteria:</u></p> <ul style="list-style-type: none"> • Unstable arterial hypertension with systolic BP $\geq 160 \text{ mm Hg}$ and/or diastolic BP $\geq 100 \text{ mm Hg}$ (confirmed at three consecutive office measurements in sitting position); if so, the patient may be re-screened after optimization of anti-hypertensive treatment • Hypertensive patients not under stable therapy according to current guideline algorithm (Mancia et al. 2013) (including stable medication for at least 4 weeks before inclusion) • Documented ischemic cardiac disease: <ul style="list-style-type: none"> - current angina pectoris or - ischemia on stress test or - untreated coronary stenosis $> 50\%$ or - history of acute myocardial infarction (AMI) or - coronary artery bypass graft (CABG, $<$ than 3 months prior to screening) or - percutaneous transluminal coronary angioplasty (PTCA) less than 3 months prior to screening. • Patients with uncontrolled recurrent persistent and permanent atrial fibrillation (AF) according to AHA/ACC/ESC guidelines (Dixon et al. 2005) (with a heart rate $> 100/\text{min}$, RACE II - (Groenveld et al. 2013, 2013)). If AF with HR $> 100/\text{min}$, the patient may be rescreened after treatment for rate control. • History of hospitalization for overt heart failure within last 12 months • History of high degree impulse conduction blocks ($>$ 2nd degree AV block type 2) • Patients after heart transplantation • Genetic hypertrophic or dilated cardiomyopathy • Dysthyroidism

	<ul style="list-style-type: none"> • Severe valvulopathy (less than 1 cm² aortic valve area, mitral insufficiency of severe grade at Doppler echo) • Congenital valvulopathies • Patients with a known history of QT prolongation (QT>450ms) or patients with documented QT prolongation (QT>450 ms) while taking medicinal products known to prolong the QT interval. • NYHA-class > II • BMI > 40 kg/m² • EF < 50%, regardless of symptoms • Known other cause (i.e. COPD) of respiratory dysfunction; patients under positive pressure (CPAP) treatment for sleep apnea syndrome may be included, provided they have been efficiently controlled by CPAP for at least one year before inclusion in the study • Moderate renal impairment defined as eGFR < 30 ml/min • Abnormal liver function tests (AST or ALT >2 X upper normal limit or patients with known hepatic impairment defined as Child-Pugh class B or higher) • Type I diabetes, complicated type II diabetes (i.e. with documented coronary macroangiopathy, cfr exclusion criterion 1 or documented other vascular complication) (National Diabetes Education Initiative - NDEI). • Patients with anemia (male: Hb <130 g/l, female: Hb <120 g/l) • Patients with bladder outlet obstruction • Patients using antimuscarinic cholinergic drugs for treatment of OAB • Current use of digitalis, bupranolol, propranolol, nebivolol (known to interfere with β3AR signalling) • Note: patients are allowed to take a β(1-2)-blocker, other than the drugs listed above (for explanation, see chapter Erreur ! Source du renvoi introuvable.). • Patients continuously treated with Sildenafil or other PDE5 inhibitors. • Current use of antifungal azole derivatives (fluconazole, itraconazole, miconazole, posaconazole, voriconazole) (known inhibitors of CYP3A4, the main metabolizer of mirabegron) • Current treatment with mirabegron or indication for future treatment with mirabegron due to other indications • Contraindication for MRI (e.g. defibrillator, ferromagnetic devices or severe claustrophobia, pacemaker - the latter only, if MRI is contraindicated) • Pregnant or nursing women • Women of child bearing potential without highly effective contraceptive measures (Clinical Trial Facilitation Group (CTFG) 9/15/2014): <ul style="list-style-type: none"> - combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) - progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) - intrauterine device (IUD)
--	---

	<ul style="list-style-type: none"> - intrauterine hormone-releasing system (IUS) - bilateral tubal occlusion - vasectomised partner - sexual abstinence (only if in agreement with the preferred and usual lifestyle of the subject) <p>while participating in the trial. There are no known interactions of the trial medication and hormone-based methods of contraception. In particular, no clinically relevant interactions have been observed when mirabegron was co-administered with therapeutic doses of a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel.</p> <ul style="list-style-type: none"> • Participation in any other interventional trial • Patients unable to give informed consent (people under legal guardianship) • Patients placed in an institution by official or court order • Contraindication to mirabegron (e.g. hypersensitivity) or any other components of the trial medication
Sample size	296 patients overall (148 patients per treatment arm) will be randomised
Therapy	<p><u>Experimental group:</u> Administration of 50 mg mirabegron once daily per os (Betmiga®, Astellas Pharma) over a period of 12 months.</p> <p><u>Control group:</u> Administration of placebo once daily per os over a period of 12 months.</p> <p><u>Verum and placebo will be manufactured by:</u> Pharmacy of the University Hospital Leipzig Liebigstr. 20 D-04103 Leipzig</p>
Biometry	<p><u>Primary endpoints:</u> Confirmatory analysis follows the intention to treat principle as close as possible and will be based on the full analysis set. In each patient, the primary endpoints will be assessed thrice: at the baseline visit, and at the 6 months and 12 months visits. Analyses of both primary endpoints are identically structured:</p> <p>Mean changes from baseline mean will be analysed using a repeated measurement linear mixed model without intercept containing the fixed, categorical effects of</p> <ul style="list-style-type: none"> • visit (baseline, 6 months, 12 months), • treatment (verum / placebo), • treatment by visit interaction • Atrial fibrillation (yes / no), • Diabetes mellitus (yes / no), <p>as well as a patient-specific, visit random effect (3-dimensional normal with a general unstructured variance covariance matrix).</p>

	<p><u>Secondary endpoints:</u></p> <p>All other MRI and echocardiographic endpoints as well as peak VO2 will be analysed along the same lines as the primary endpoints. Time courses of metabolic parameters and specific biomarkers will be described.</p> <p>Adverse and serious adverse events will be compared by chi-square tests. Odds ratios with 95% confidence intervals will be provided.</p>
Trial Duration	<p>Individual treatment period: 12 months treatment per patient with an additional follow-up-phone visit at month 13</p> <p>Trial:</p> <ul style="list-style-type: none">• First patient in: April 2016• Patient-screening and recruitment: 33 months• Last patient out (planned): December 2019• Final analysis (planned) December 2020